Description
Intended use:
Cartilage Oligomeric Matrix Protein is an abundant cartilage glycoprotein also found in tendon and other tissues. Synthesized by chondrocytes, synovial and other skeleton cells. Intact and fragmented COMP in synovial fluid or serum is correlating to cartilage degradation in OA and RA
RA disease: COMP levels can be used for monitoring the effect of anti-rheumatic drug therapy. Treatment with TNF-α blockers or adalimumab, suppresses COMP levels.
OA disease: Changes in serum COMP are prognostic for disease progression in knee OA. A significant serum COMP increase during the first year indicates progressive disease. Baseline COMP levels do not have prognostic significance.